Aeglea BioTherapeutics

Aeglea Biotherapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.

Astra Space

VirnetX

Penny stocks to buy for under $1 but are they worth the risk? The post 3 Top Penny Stocks Under $1 To Watch Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Top Penny Stocks Under $1 To Watch Before Next Week

Aeglea BioTherapeutics (AGLE) announces failure to meet goals in the phase I/II study of pegtarviliase for the treatment of Classical Homocystinuria. The stock is down 26% following the news.

Aeglea (AGLE) Plunges 26% After Rare Disorder Drug Study Fails

AUSTIN, Texas , March 17, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced the company granted non-qualified equity awards to four new employees with a grant date of March 17, 2023, as equity inducement awards outside of the company's 2016 Equity Incentive Plan, but under the terms of the company's 2018 Equity Inducement Plan. The awards were granted as material inducements to the employees entering into employment with Aeglea in accordance with Rule 5635(c)(4) of the Nasdaq Listing Rules.

Aeglea BioTherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aeglea (AGLE) delivered earnings and revenue surprises of 10% and 1.18%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Aeglea Biotherapeutics (AGLE) Reports Q4 Loss, Lags Revenue Estimates

Jeffrey Goldberg, experienced biotech executive, appointed president and CEO; further strengthened senior management team with appointments of chief medical officer and chief product officer $57.3 million of cash, cash equivalents, marketable securities, and restricted cash as of December 31, 2022, which is expected to fund operations into the fourth quarter of 2023 AUSTIN, Texas , March 2, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced financial results for the fourth quarter and full year 2022, and provided program updates. "Since joining the company, I have been impressed by the programs and the potential impact that they may have on patient lives.

Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Program Updates

Streamlining of organization to focus on near-term deliverables for pegtarviliase in Homocystinuria and long-term value creation Cortney Caudill, M.B.A., has been promoted to the newly created role of chief product officer to increase focus and efficiency in the advancement of clinical programs AUSTIN, Texas , Jan. 6, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced an update to its corporate structure.

Aeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational Efficiency

Aeglea (AGLE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Aeglea (AGLE) Moves to Buy: Rationale Behind the Upgrade

AUSTIN, Texas, Dec. 2, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that the compensation committee of its board of directors has granted non-qualified stock options to purchase an aggregate of 1,884,838 shares of Aeglea's common stock to Jeffrey M. Goldberg as a material inducement to his appointment as the chief executive officer of Aeglea in accordance with Rule 5635(c)(4) of the Nasdaq Listing Rules.

Aeglea BioTherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

AUSTIN, Texas , Nov. 30, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced the appointment of Jeffrey M. Goldberg as president, chief executive officer and member of the board of directors effective November 29, 2022.

Aeglea BioTherapeutics Appoints Jeffrey M. Goldberg as Chief Executive Officer

AUSTIN, Texas , Nov. 15, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that Linda Neuman, M.D., M.B.A. has been appointed chief medical officer.

Aeglea BioTherapeutics Appoints Linda Neuman, M.D., M.B.A, to Chief Medical Officer

Berkeley Lights, Inc.

Invitae

OmniAb Inc

Hot penny stocks to watch after October's CPI report. The post Best Penny Stocks To Buy Now That CPI Is Out?

Best Penny Stocks To Buy Now That CPI Is Out? 4 To Watch Before Next Week

Aeglea (AGLE) delivered earnings and revenue surprises of 20.83% and 72.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Aeglea Biotherapeutics (AGLE) Reports Q3 Loss, Misses Revenue Estimates

Interim Clinical Data from Phase 1/2 Trial of Pegtarviliase Expected in Fourth Quarter of 2022; Currently Dosing Cohort 3 at 1.35 mg/kg MAA for Pegzilarginase for the Treatment of Arginase 1 Deficiency Accepted for Review by the EMA $75.2 Million of Cash as of September 30, 2022; Runway into Fourth Quarter of 2023 AUSTIN, Texas, Nov. 3, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced financial results for the third quarter ended September 30, 2022 and provided program updates. "With our recent corporate restructuring we have prioritized our pegtarviliase program to optimize our resources and maximize Aeglea's success.

Aeglea BioTherapeutics Reports Third Quarter 2022 Financial Results and Provides Program Updates

Ardagh Metal Packaging SA

Reviva Pharmaceuticals

Penny stocks with bullish analyst ratings. Time to buy or avoid entirely?

4 Penny Stocks To Buy According To Analysts Right Now

Credit Suisse

Quanergy Systems

This is why penny stocks are so volati The post Why Are Penny Stocks Volatile? 3 Reasons and How to Profit  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Why Are Penny Stocks Volatile? 3 Reasons and How to Profit

Data I/O

Geron

Perpetua Resources Corp

Penny stocks to watch this week with news. The post 5 Top Penny Stocks To Watch With News Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Top Penny Stocks To Watch With News Before Next Week

Event to be Held Thursday, October 27 th at 10 AM ET AUSTIN, Texas , Oct. 19, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced that it will host a key opinion leader (KOL) webinar on Classical Homocystinuria, and Aeglea's potential treatment and lead clinical asset pegtarviliase on Thursday, October 27, 2022 at 10:00 AM Eastern Time. The webinar will feature KOL Harvey Levy, MD, who will discuss the unmet medical need and current treatment landscape for patients suffering from Classical Homocystinuria, also known as cystathionine beta synthase (CBS) deficiency.

Aeglea BioTherapeutics Hosting Key Opinion Leader Webinar on Classical Homocystinuria and Pegtarviliase's Potential Role in Treatment

AUSTIN, Texas , Oct. 4, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that dosing in the third cohort of the Phase 1/2 clinical trial of pegtarviliase for the treatment of Classical Homocystinuria is underway. Patients in this cohort are receiving 1.35 mg/kg of pegtarviliase once weekly administered via subcutaneous injection; patients in cohorts 1 and 2 received doses of 0.15 mg/kg and 0.45 mg/kg, respectively.

Aeglea BioTherapeutics Provides Clinical Progress and Regulatory Update for Homocystinuria Program

AUSTIN, Texas , Aug. 29, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced oral and poster presentations at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2022 being held in Freiburg, Germany August 30 – September 2. The presentations include perspectives on dietary management of Homocystinuria, which will be given as both an oral and poster presentation, as well as additional safety and efficacy data from the PEACE Phase 3 study of pegzilarginase for the treatment of patients with Arginase 1 Deficiency.

Aeglea BioTherapeutics Announces Presentations at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2022

Paltalk

Astrotech

OppFi

The Dow Jones tumbled by over 500 points on Friday. Investors, meanwhile, focused on some notable insider trades.

Paltalk And 3 Other Stocks Under $3 Insiders Are Aggressively Buying

Aeglea (AGLE) announces a corporate restructuring plan to prioritize the development of AGLE-177 for patients living with homocystinuria. The company's current CEO resigns.

Aeglea (AGLE) Down on Corporate Restructuring, CEO Steps Down

Prioritizing  Resources and Focus on AGLE-177 and the Completion of the Ongoing Phase 1/2 Trial in Homocystinuria with Interim Clinical Data Expected in Q4 of 2022 Dr. Anthony Quinn, President, CEO and Board Member, has Stepped Down from His Current Positions and Transitioned to an Advisory Role Corporate Restructuring to Extend Runway into Q4 2023 AUSTIN, Texas , Aug. 24, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced a leadership transition and corporate restructuring to focus resources on AGLE-177 in development for patients living with Homocystinuria. The restructuring has further reduced the headcount of the Company resulting in an approximately 25% reduction year-to-date.

Aeglea BioTherapeutics Announces Leadership Transition and Corporate Restructuring

Aeglea BioTherapeutics (AGLE) seeks a nod for its lead candidate, pegzilarginase, for treating ARG1-D in the European Union. Stock surges post announcement.

Aeglea BioTherapeutics (AGLE) Seeks EU Nod for ARG1-D Treatment

Applied DNA Sciences

Volcon

Here's what you need to know about trading penny stocks on August 22nd The post Buying Penny Stocks Right Now? 3 to Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Buying Penny Stocks Right Now? 3 to Watch This Week

Party City Holdco

Sonder Holdings

Penny stocks with unusual options activity today. The post 4 Penny Stocks To Watch With Bullish Buys From Options Traders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

News for Aeglea BioTherapeutics Stock (AGLE)